research Increased Polyamine Concentrations in the Hair of Cancer Patients
Hair can be used to measure cancer-related chemicals noninvasively.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of FP-receptor activation
Topical latanoprost acid at 0.05% concentration improved hair growth in women with androgenetic alopecia.
research Planar Proton Minibeam Irradiation Elicits Spatially Confined DNA Damage in a Human Epidermis Model
Proton minibeam radiotherapy may reduce skin side effects by causing localized DNA damage.
research XP Endo Finisher-R and PUI as supplementary methods to remove root filling materials from curved canals
XP-endo Finisher R removes more root filling material than PUI in curved canals.
research 1330 The possible role of PTEN-induced kinase 1-mediated mitophagy by regulating inflammasome activation in the pathogenesis of alopecia areata
Activating mitophagy may help manage a key immune response involved in the hair loss condition alopecia areata.
research 591 Chromatin architectural protein CTCF regulates terminal keratinocyte differentiation in the developing epidermis and hair follicles
CTCF protein is essential for skin and hair follicle development in mice.
research 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
Particulate matter causes inflammation in hair cells, potentially harming hair growth.
research The calcium-binding protein calretinin is a marker of the companion cell layer of the human hair follicle
Calretinin identifies the companion cell layer in human hair follicles.
research 502 The stress-responsive secretory protein adrenomedullin 2 potently induces cell cycle arrest and apoptosis in human hair follicles
Adrenomedullin 2 stops cell growth and causes cell death in human hair follicles.
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.